Literature DB >> 32250341

Transcriptional and cytopathological hallmarks of FSHD in chronic DUX4-expressing mice.

Darko Bosnakovski1,2,3, Ahmed S Shams1,2,4, Ce Yuan5, Meiricris T da Silva1,2, Elizabeth T Ener1,2, Cory W Baumann6, Angus J Lindsay6, Mayank Verma7, Atsushi Asakura7, Dawn A Lowe6, Michael Kyba1,2.   

Abstract

Facioscapulohumeral muscular dystrophy (FSHD) is caused by loss of repression of the DUX4 gene; however, the DUX4 protein is rare and difficult to detect in human muscle biopsies, and pathological mechanisms are obscure. FSHD is also a chronic disease that progresses slowly over decades. We used the sporadic, low-level, muscle-specific expression of DUX4 enabled by the iDUX4pA-HSA mouse to develop a chronic long-term muscle disease model. After 6 months of extremely low sporadic DUX4 expression, dystrophic muscle presented hallmarks of FSHD histopathology, including muscle degeneration, capillary loss, fibrosis, and atrophy. We investigated the transcriptional profile of whole muscle as well as endothelial cells and fibroadiopogenic progenitors (FAPs). Strikingly, differential gene expression profiles of both whole muscle and, to a lesser extent, FAPs, showed significant overlap with transcriptional profiles of MRI-guided human FSHD muscle biopsies. These results demonstrate a pathophysiological similarity between disease in muscles of iDUX4pA-HSA mice and humans with FSHD, solidifying the value of chronic rare DUX4 expression in mice for modeling pathological mechanisms in FSHD and highlighting the importance FAPs in this disease.

Entities:  

Keywords:  Adult stem cells; Fibrosis; Muscle Biology; Neuroscience; Skeletal muscle

Mesh:

Substances:

Year:  2020        PMID: 32250341      PMCID: PMC7190912          DOI: 10.1172/JCI133303

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  48 in total

1.  Wnt/β-catenin signaling suppresses DUX4 expression and prevents apoptosis of FSHD muscle cells.

Authors:  Gregory J Block; Divya Narayanan; Amanda M Amell; Lisa M Petek; Kathryn C Davidson; Thomas D Bird; Rabi Tawil; Randall T Moon; Daniel G Miller
Journal:  Hum Mol Genet       Date:  2013-07-02       Impact factor: 6.150

2.  Mesenchymal Stromal Cells Are Required for Regeneration and Homeostatic Maintenance of Skeletal Muscle.

Authors:  Michael N Wosczyna; Colin T Konishi; Edgar E Perez Carbajal; Theodore T Wang; Rachel A Walsh; Qiang Gan; Mark W Wagner; Thomas A Rando
Journal:  Cell Rep       Date:  2019-05-14       Impact factor: 9.423

3.  DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle.

Authors:  Zizhen Yao; Lauren Snider; Judit Balog; Richard J L F Lemmers; Silvère M Van Der Maarel; Rabi Tawil; Stephen J Tapscott
Journal:  Hum Mol Genet       Date:  2014-05-26       Impact factor: 6.150

4.  DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy.

Authors:  Linda N Geng; Zizhen Yao; Lauren Snider; Abraham P Fong; Jennifer N Cech; Janet M Young; Silvere M van der Maarel; Walter L Ruzzo; Robert C Gentleman; Rabi Tawil; Stephen J Tapscott
Journal:  Dev Cell       Date:  2011-12-29       Impact factor: 12.270

5.  Denervation-activated STAT3-IL-6 signalling in fibro-adipogenic progenitors promotes myofibres atrophy and fibrosis.

Authors:  Luca Madaro; Magda Passafaro; David Sala; Usue Etxaniz; Francesca Lugarini; Daisy Proietti; Maria Vittoria Alfonsi; Chiara Nicoletti; Sole Gatto; Marco De Bardi; Ricardo Rojas-García; Lorenzo Giordani; Sara Marinelli; Vittoria Pagliarini; Claudio Sette; Alessandra Sacco; Pier Lorenzo Puri
Journal:  Nat Cell Biol       Date:  2018-07-26       Impact factor: 28.824

6.  Endogenous DUX4 expression in FSHD myotubes is sufficient to cause cell death and disrupts RNA splicing and cell migration pathways.

Authors:  Amanda M Rickard; Lisa M Petek; Daniel G Miller
Journal:  Hum Mol Genet       Date:  2015-08-05       Impact factor: 6.150

7.  Essential nucleotide- and protein-dependent functions of Actb/β-actin.

Authors:  Xiaobai Patrinostro; Pallabi Roy; Angus Lindsay; Christopher M Chamberlain; Lauren J Sundby; Colby G Starker; Daniel F Voytas; James M Ervasti; Benjamin J Perrin
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-16       Impact factor: 11.205

8.  PAX7 target genes are globally repressed in facioscapulohumeral muscular dystrophy skeletal muscle.

Authors:  Christopher R S Banerji; Maryna Panamarova; Husam Hebaishi; Robert B White; Frédéric Relaix; Simone Severini; Peter S Zammit
Journal:  Nat Commun       Date:  2017-12-18       Impact factor: 14.919

9.  A novel P300 inhibitor reverses DUX4-mediated global histone H3 hyperacetylation, target gene expression, and cell death.

Authors:  Darko Bosnakovski; Meiricris T da Silva; Sithara T Sunny; Elizabeth T Ener; Erik A Toso; Ce Yuan; Ziyou Cui; Michael A Walters; Ajit Jadhav; Michael Kyba
Journal:  Sci Adv       Date:  2019-09-11       Impact factor: 14.136

10.  Immunohistochemical Characterization of Facioscapulohumeral Muscular Dystrophy Muscle Biopsies.

Authors:  Jeffrey M Statland; Karen J Odrzywolski; Bharati Shah; Don Henderson; Alex F Fricke; Silvère M van der Maarel; Stephen J Tapscott; Rabi Tawil
Journal:  J Neuromuscul Dis       Date:  2015
View more
  22 in total

1.  It's not all about muscle: fibroadipogenic progenitors contribute to facioscapulohumeral muscular dystrophy.

Authors:  Carlo Serra; Kathryn R Wagner
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

2.  Proximity ligation assay to detect DUX4 protein in FSHD1 muscle: a pilot study.

Authors:  Mary Lou Beermann; Sachiko Homma; Jeffrey Boone Miller
Journal:  BMC Res Notes       Date:  2022-05-10

3.  Canine DUXC: implications for DUX4 retrotransposition and preclinical models of FSHD.

Authors:  Chao-Jen Wong; Jennifer L Whiddon; Ashlee T Langford; Andrea E Belleville; Stephen J Tapscott
Journal:  Hum Mol Genet       Date:  2022-05-19       Impact factor: 5.121

Review 4.  Cellular and animal models for facioscapulohumeral muscular dystrophy.

Authors:  Alec M DeSimone; Justin Cohen; Monkol Lek; Angela Lek
Journal:  Dis Model Mech       Date:  2020-10-28       Impact factor: 5.758

Review 5.  Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an update.

Authors:  Teresa Schätzl; Lars Kaiser; Hans-Peter Deigner
Journal:  Orphanet J Rare Dis       Date:  2021-03-12       Impact factor: 4.123

6.  Defining and identifying satellite cell-opathies within muscular dystrophies and myopathies.

Authors:  Massimo Ganassi; Francesco Muntoni; Peter S Zammit
Journal:  Exp Cell Res       Date:  2021-11-03       Impact factor: 3.905

7.  Facioscapulohumeral dystrophy transcriptome signatures correlate with different stages of disease and are marked by different MRI biomarkers.

Authors:  Anita van den Heuvel; Saskia Lassche; Karlien Mul; Anna Greco; David San León Granado; Arend Heerschap; Benno Küsters; Stephen J Tapscott; Nicol C Voermans; Baziel G M van Engelen; Silvère M van der Maarel
Journal:  Sci Rep       Date:  2022-01-26       Impact factor: 4.379

8.  Prdm16-mediated H3K9 methylation controls fibro-adipogenic progenitors identity during skeletal muscle repair.

Authors:  Beatrice Biferali; Valeria Bianconi; Daniel Fernandez Perez; Sophie Pöhle Kronawitter; Fabrizia Marullo; Roberta Maggio; Tiziana Santini; Federica Polverino; Stefano Biagioni; Vincenzo Summa; Carlo Toniatti; Diego Pasini; Sigmar Stricker; Romano Di Fabio; Fulvio Chiacchiera; Giovanna Peruzzi; Chiara Mozzetta
Journal:  Sci Adv       Date:  2021-06-02       Impact factor: 14.136

9.  Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model.

Authors:  Ngoc Lu-Nguyen; Alberto Malerba; Shan Herath; George Dickson; Linda Popplewell
Journal:  Hum Mol Genet       Date:  2021-07-09       Impact factor: 6.150

Review 10.  The prospects of targeting DUX4 in facioscapulohumeral muscular dystrophy.

Authors:  Linde F Bouwman; Silvère M van der Maarel; Jessica C de Greef
Journal:  Curr Opin Neurol       Date:  2020-10       Impact factor: 6.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.